000120096 001__ 120096
000120096 005__ 20240228135011.0
000120096 0247_ $$2doi$$a10.1007/s00401-013-1213-7
000120096 0247_ $$2pmid$$apmid:24264598
000120096 0247_ $$2pmc$$apmc:PMC3895219
000120096 0247_ $$2ISSN$$a0001-6322
000120096 0247_ $$2ISSN$$a1432-0533
000120096 0247_ $$2altmetric$$aaltmetric:1932063
000120096 037__ $$aDKFZ-2017-00683
000120096 041__ $$aeng
000120096 082__ $$a610
000120096 1001_ $$aGottardo, Nicholas G$$b0
000120096 245__ $$aMedulloblastoma Down Under 2013: a report from the third annual meeting of the International Medulloblastoma Working Group.
000120096 260__ $$aBerlin$$bSpringer$$c2014
000120096 3367_ $$2DRIVER$$aarticle
000120096 3367_ $$2DataCite$$aOutput Types/Journal article
000120096 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1490793518_22980
000120096 3367_ $$2BibTeX$$aARTICLE
000120096 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000120096 3367_ $$00$$2EndNote$$aJournal Article
000120096 520__ $$aMedulloblastoma is curable in approximately 70% of patients. Over the past decade, progress in improving survival using conventional therapies has stalled, resulting in reduced quality of life due to treatment-related side effects, which are a major concern in survivors. The vast amount of genomic and molecular data generated over the last 5-10 years encourages optimism that improved risk stratification and new molecular targets will improve outcomes. It is now clear that medulloblastoma is not a single-disease entity, but instead consists of at least four distinct molecular subgroups: WNT/Wingless, Sonic Hedgehog, Group 3, and Group 4. The Medulloblastoma Down Under 2013 meeting, which convened at Bunker Bay, Australia, brought together 50 leading clinicians and scientists. The 2-day agenda included focused sessions on pathology and molecular stratification, genomics and mouse models, high-throughput drug screening, and clinical trial design. The meeting established a global action plan to translate novel biologic insights and drug targeting into treatment regimens to improve outcomes. A consensus was reached in several key areas, with the most important being that a novel classification scheme for medulloblastoma based on the four molecular subgroups, as well as histopathologic features, should be presented for consideration in the upcoming fifth edition of the World Health Organization's classification of tumours of the central nervous system. Three other notable areas of agreement were as follows: (1) to establish a central repository of annotated mouse models that are readily accessible and freely available to the international research community; (2) to institute common eligibility criteria between the Children's Oncology Group and the International Society of Paediatric Oncology Europe and initiate joint or parallel clinical trials; (3) to share preliminary high-throughput screening data across discovery labs to hasten the development of novel therapeutics. Medulloblastoma Down Under 2013 was an effective forum for meaningful discussion, which resulted in enhancing international collaborative clinical and translational research of this rare disease. This template could be applied to other fields to devise global action plans addressing all aspects of a disease, from improved disease classification, treatment stratification, and drug targeting to superior treatment regimens to be assessed in cooperative international clinical trials.
000120096 536__ $$0G:(DE-HGF)POF3-312$$a312 - Functional and structural genomics (POF3-312)$$cPOF3-312$$fPOF III$$x0
000120096 588__ $$aDataset connected to CrossRef, PubMed,
000120096 650_7 $$2NLM Chemicals$$aAntineoplastic Agents
000120096 7001_ $$aHansford, Jordan R$$b1
000120096 7001_ $$aMcGlade, Jacqueline P$$b2
000120096 7001_ $$aAlvaro, Frank$$b3
000120096 7001_ $$aAshley, David M$$b4
000120096 7001_ $$aBailey, Simon$$b5
000120096 7001_ $$aBaker, David L$$b6
000120096 7001_ $$aBourdeaut, Franck$$b7
000120096 7001_ $$aCho, Yoon-Jae$$b8
000120096 7001_ $$aClay, Moira$$b9
000120096 7001_ $$aClifford, Steven C$$b10
000120096 7001_ $$aCohn, Richard J$$b11
000120096 7001_ $$aCole, Catherine H$$b12
000120096 7001_ $$aDallas, Peter B$$b13
000120096 7001_ $$aDownie, Peter$$b14
000120096 7001_ $$aDoz, François$$b15
000120096 7001_ $$aEllison, David W$$b16
000120096 7001_ $$aEndersby, Raelene$$b17
000120096 7001_ $$aFisher, Paul G$$b18
000120096 7001_ $$aHassall, Timothy$$b19
000120096 7001_ $$aHeath, John A$$b20
000120096 7001_ $$aHii, Hilary L$$b21
000120096 7001_ $$0P:(DE-He78)551bb92841f634070997aa168d818492$$aJones, David$$b22$$udkfz
000120096 7001_ $$aJunckerstorff, Reimar$$b23
000120096 7001_ $$aKellie, Stewart$$b24
000120096 7001_ $$0P:(DE-He78)4c28e2aade5f44d8eca9dd8e97638ec8$$aKool, Marcel$$b25$$udkfz
000120096 7001_ $$aKotecha, Rishi S$$b26
000120096 7001_ $$0P:(DE-He78)e13b4363c5fe858044ef8a39c02c870c$$aLichter, Peter$$b27$$udkfz
000120096 7001_ $$aLaughton, Stephen J$$b28
000120096 7001_ $$aLee, Sharon$$b29
000120096 7001_ $$aMcCowage, Geoff$$b30
000120096 7001_ $$0P:(DE-HGF)0$$aNorthcott, Paul A$$b31
000120096 7001_ $$aOlson, James M$$b32
000120096 7001_ $$aPacker, Roger J$$b33
000120096 7001_ $$0P:(DE-He78)f746aa965c4e1af518b016de3aaff5d9$$aPfister, Stefan$$b34$$udkfz
000120096 7001_ $$aPietsch, Torsten$$b35
000120096 7001_ $$aPizer, Barry$$b36
000120096 7001_ $$aPomeroy, Scott L$$b37
000120096 7001_ $$aRemke, Marc$$b38
000120096 7001_ $$aRobinson, Giles W$$b39
000120096 7001_ $$aRutkowski, Stefan$$b40
000120096 7001_ $$aSchoep, Tobias$$b41
000120096 7001_ $$aShelat, Anang A$$b42
000120096 7001_ $$aStewart, Clinton F$$b43
000120096 7001_ $$aSullivan, Michael$$b44
000120096 7001_ $$aTaylor, Michael D$$b45
000120096 7001_ $$aWainwright, Brandon$$b46
000120096 7001_ $$aWalwyn, Thomas$$b47
000120096 7001_ $$aWeiss, William A$$b48
000120096 7001_ $$aWilliamson, Dan$$b49
000120096 7001_ $$aGajjar, Amar$$b50
000120096 773__ $$0PERI:(DE-600)1458410-4$$a10.1007/s00401-013-1213-7$$gVol. 127, no. 2, p. 189 - 201$$n2$$p189 - 201$$tActa neuropathologica$$v127$$x1432-0533$$y2014
000120096 909CO $$ooai:inrepo02.dkfz.de:120096$$pVDB
000120096 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)551bb92841f634070997aa168d818492$$aDeutsches Krebsforschungszentrum$$b22$$kDKFZ
000120096 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)4c28e2aade5f44d8eca9dd8e97638ec8$$aDeutsches Krebsforschungszentrum$$b25$$kDKFZ
000120096 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)e13b4363c5fe858044ef8a39c02c870c$$aDeutsches Krebsforschungszentrum$$b27$$kDKFZ
000120096 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-HGF)0$$aDeutsches Krebsforschungszentrum$$b31$$kDKFZ
000120096 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)f746aa965c4e1af518b016de3aaff5d9$$aDeutsches Krebsforschungszentrum$$b34$$kDKFZ
000120096 9131_ $$0G:(DE-HGF)POF3-312$$1G:(DE-HGF)POF3-310$$2G:(DE-HGF)POF3-300$$3G:(DE-HGF)POF3$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vFunctional and structural genomics$$x0
000120096 9141_ $$y2014
000120096 915__ $$0StatID:(DE-HGF)0420$$2StatID$$aNationallizenz
000120096 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bACTA NEUROPATHOL : 2015
000120096 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS
000120096 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline
000120096 915__ $$0StatID:(DE-HGF)0310$$2StatID$$aDBCoverage$$bNCBI Molecular Biology Database
000120096 915__ $$0StatID:(DE-HGF)0600$$2StatID$$aDBCoverage$$bEbsco Academic Search
000120096 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bASC
000120096 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bThomson Reuters Master Journal List
000120096 915__ $$0StatID:(DE-HGF)0110$$2StatID$$aWoS$$bScience Citation Index
000120096 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection
000120096 915__ $$0StatID:(DE-HGF)0111$$2StatID$$aWoS$$bScience Citation Index Expanded
000120096 915__ $$0StatID:(DE-HGF)1030$$2StatID$$aDBCoverage$$bCurrent Contents - Life Sciences
000120096 915__ $$0StatID:(DE-HGF)1050$$2StatID$$aDBCoverage$$bBIOSIS Previews
000120096 915__ $$0StatID:(DE-HGF)9910$$2StatID$$aIF >= 10$$bACTA NEUROPATHOL : 2015
000120096 9201_ $$0I:(DE-He78)B062-20160331$$kB062$$lPädiatrische Neuroonkologie$$x0
000120096 9201_ $$0I:(DE-He78)B060-20160331$$kB060$$lMolekulare Genetik$$x1
000120096 980__ $$ajournal
000120096 980__ $$aVDB
000120096 980__ $$aI:(DE-He78)B062-20160331
000120096 980__ $$aI:(DE-He78)B060-20160331
000120096 980__ $$aUNRESTRICTED